Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.
Shagun Arora, MD, assistant clinical professor, Division of Hematology/Oncology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the rapidly advancing multiple myeloma treatment landscape.
The armamentarium in multiple myeloma has changed significantly in recent years with the approvals of several triplet regimens, says Arora. Moreover, triplet regimens should be utilized when possible to deepen remissions and prolong progression-free survival.
With a number of encouraging therapies in the pipeline, future research efforts should focus on identifying the optimal sequencing strategy for these patients, Arora explains.
Moreover, factors such as comorbidities and quality of life should be kept in mind during treatment selection, Arora concludes.